New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease


Cite item

Full Text

Abstract

:This patent describes the novel pyrroloppyrimidine compounds as LRRK2 kinase inhibitors. The patent includes the synthesis of compounds, compositions containing them and their use in the treatment of or prevention of diseases associated with LRRK2 kinase activity, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).

About the authors

Surya De

Chemistry, Conju-Probe

Author for correspondence.
Email: info@benthamscience.net

References

  1. Trinh, J.; Farrer, M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol., 2013, 9(8), 445-454. doi: 10.1038/nrneurol.2013.132 PMID: 23857047
  2. Paisán-Ruiz, C.; Lewis, P.A.; Singleton, A.B. LRRK2: Cause, risk, and mechanism. J. Parkinsons Dis., 2013, 3(2), 85-103. doi: 10.3233/JPD-130192 PMID: 23938341
  3. Gilks, W.P.; Abou-Sleiman, P.M.; Gandhi, S.; Jain, S.; Singleton, A.; Lees, A.J.; Shaw, K.; Bhatia, K.P.; Bonifati, V.; Quinn, N.P.; Lynch, J.; Healy, D.G.; Holton, J.L.; Revesz, T.; Wood, N.W. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet, 2005, 365(9457), 415-416. doi: 10.1016/S0140-6736(05)17830-1 PMID: 15680457
  4. Ross, O.A.; Soto-Ortolaza, A.I.; Heckman, M.G.; Aasly, J.O.; Abahuni, N.; Annesi, G.; Bacon, J.A.; Bardien, S.; Bozi, M.; Brice, A.; Brighina, L.; Van Broeckhoven, C.; Carr, J.; Chartier-Harlin, M.C.; Dardiotis, E.; Dickson, D.W.; Diehl, N.N.; Elbaz, A.; Ferrarese, C.; Ferraris, A.; Fiske, B.; Gibson, J.M.; Gibson, R.; Hadjigeorgiou, G.M.; Hattori, N.; Ioannidis, J.P.A.; Jasinska-Myga, B.; Jeon, B.S.; Kim, Y.J.; Klein, C.; Kruger, R.; Kyratzi, E.; Lesage, S.; Lin, C.H.; Lynch, T.; Maraganore, D.M.; Mellick, G.D.; Mutez, E.; Nilsson, C.; Opala, G.; Park, S.S.; Puschmann, A.; Quattrone, A.; Sharma, M.; Silburn, P.A.; Sohn, Y.H.; Stefanis, L.; Tadic, V.; Theuns, J.; Tomiyama, H.; Uitti, R.J.; Valente, E.M.; van de Loo, S.; Vassilatis, D.K.; Vilariño-Güell, C.; White, L.R.; Wirdefeldt, K.; Wszolek, Z.K.; Wu, R.M.; Farrer, M.J. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: A case–control study. Lancet Neurol., 2011, 10(10), 898-908. doi: 10.1016/S1474-4422(11)70175-2 PMID: 21885347
  5. Jaleel, M.; Nichols, R.J.; Deak, M.; Campbell, D.G.; Gillardon, F.; Knebel, A.; Alessi, D.R. LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson’s disease mutants affect kinase activity. Biochem. J., 2007, 405(2), 307-317. doi: 10.1042/BJ20070209 PMID: 17447891
  6. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 2010, 430(3), 405-413. doi: 10.1042/BJ20100784 PMID: 20659021
  7. Guo, L.; Gandhi, P.N.; Wang, W.; Petersen, R.B.; Wilson-Delfosse, A.L.; Chen, S.G. The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Exp. Cell Res., 2007, 313(16), 3658-3670. doi: 10.1016/j.yexcr.2007.07.007 PMID: 17706965
  8. West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; Dawson, T.M. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 2007, 16(2), 223-232. doi: 10.1093/hmg/ddl471 PMID: 17200152
  9. Wile, D.J.; Agarwal, P.A.; Schulzer, M.; Mak, E.; Dinelle, K.; Shahinfard, E.; Vafai, N.; Hasegawa, K.; Zhang, J.; McKenzie, J.; Neilson, N.; Strongosky, A.; Uitti, R.J.; Guttman, M.; Zabetian, C.P.; Ding, Y.S.; Adam, M.; Aasly, J.; Wszolek, Z.K.; Farrer, M.; Sossi, V.; Stoessl, A.J. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol., 2017, 16(5), 351-359. doi: 10.1016/S1474-4422(17)30056-X PMID: 28336296
  10. Sosero, Y.L.; Gan-Or, Z. LRRK2 and Parkinson’s disease: From genetics to targeted therapy. Ann. Clin. Transl. Neurol., 2023, 10(6), 850-864. doi: 10.1002/acn3.51776 PMID: 37021623

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers